{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:48Z","timestamp":1790612208789,"version":"4.1.0"},"reference-count":140,"publisher":"Tech Science Press","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.068395","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:06:16Z","timestamp":1757581576000},"page":"3269-3292","source":"Crossref","is-referenced-by-count":13,"title":["Reprogramming the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: Therapeutic Targets and Innovations"],"prefix":"10.32604","volume":"33","author":[{"given":"Bruno","family":"\u0160piljak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Poposki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stjepanka","family":"Le\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cells13121018","article-title":"Overcoming resistance to standard-of-care therapies for head and neck squamous cell carcinomas","volume":"13","author":"Gauss","year":"2024","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1038\/s41598-025-89053-6","article-title":"Survival and data-driven phenotypes in head and neck cancer","volume":"15","author":"Heinolainen","year":"2025","journal-title":"Sci Rep"},{"key":"ref3","first-page":"488","article-title":"Local cancer recurrence: the realities, challenges, and opportunities for new therapies","volume":"68","author":"Mahvi","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-019-0983-5","article-title":"Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review","volume":"18","author":"Peltanova","year":"2019","journal-title":"Mol Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-021-00503-9","article-title":"Correction: tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy","volume":"6","author":"Bhat","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.oraloncology.2017.09.012","article-title":"Liquid biopsy: an emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs)","volume":"74","author":"Economopoulou","year":"2017","journal-title":"Oral Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","article-title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","volume":"29","author":"Colevas","year":"2018","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"105301","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"eBioMedicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/jpm13111616","article-title":"Role of microenvironmental components in head and neck squamous cell carcinoma","volume":"13","author":"Jumaniyazova","year":"2023","journal-title":"J Pers Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14728222.2018.1451514","article-title":"FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity","volume":"22","author":"Whiteside","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","article-title":"The role of tumor-associated macrophages in tumor immune evasion","volume":"150","author":"Huang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"ref21","author":"Barahona-Lopez","year":"2025","journal-title":"Advancements in oral cancer\u2014modern diagnostics, altered molecular profile and therapeutic strategies"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J Hematol Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","article-title":"Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Pei","year":"2023","journal-title":"Mol Cancer"},{"key":"ref25","first-page":"237","article-title":"Overcoming cancer treatment resistance: unraveling the role of cancer-associated fibroblasts","volume":"5","author":"Wang","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12967-025-06306-8","article-title":"Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","article-title":"Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives","volume":"16","author":"Gu","year":"2025","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J Biomed Sci"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.trecan.2019.02.007","article-title":"Immune evasion by head and neck cancer: foundations for combination therapy","volume":"5","author":"Horton","year":"2019","journal-title":"Trends Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1021609","DOI":"10.3389\/fonc.2022.1021609","article-title":"The role of T-cells in head and neck squamous cell carcinoma: from immunity to immunotherapy","volume":"12","author":"Damasio","year":"2022","journal-title":"Front Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-025-00886-w","article-title":"Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives","volume":"9","author":"Liu","year":"2025","journal-title":"npj Precis Onc"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3389\/fimmu.2020.01721","article-title":"The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer","volume":"11","author":"Qiao","year":"2020","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.3390\/ijms22105123","article-title":"PD-1\/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects","volume":"22","author":"Munari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1758835920937612","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3389\/fonc.2018.00532","article-title":"Crosstalk between PD-1\/PD-L1 blockade and its combinatorial therapies in tumor immune microenvironment: a focus on HNSCC","volume":"8","author":"Lin","year":"2018","journal-title":"Front Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cancers11071033","article-title":"PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging\u2014a literature review","volume":"11","author":"Planes-Laine","year":"2019","journal-title":"Cancers"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.3390\/curroncol29060334","article-title":"Current and future biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma","volume":"29","author":"Park","year":"2022","journal-title":"Curr Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cancers17050880","article-title":"Revolutionary cancer therapy for personalization and improved efficacy: strategies to overcome resistance to immune checkpoint inhibitor therapy","volume":"17","author":"Almawash","year":"2025","journal-title":"Cancers"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e70196","DOI":"10.1002\/iid3.70196","article-title":"Immune checkpoint molecules: a review on pathways and immunotherapy implications","volume":"13","author":"Rezazadeh-Gavgani","year":"2025","journal-title":"Immun Inflamm Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8 + T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"104460","DOI":"10.1016\/j.oraloncology.2019.104460","article-title":"Immunotherapy for head and neck cancer: recent advances and future directions","volume":"99","author":"Cramer","year":"2019","journal-title":"Oral Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"107145","DOI":"10.1016\/j.oraloncology.2024.107145","article-title":"Immunotherapeutic strategies beyond the PD-1\/PD-L1 pathway in head and neck squamous cell carcinoma-A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA","volume":"161","author":"Struckmeier","year":"2025","journal-title":"Oral Oncol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"613114","DOI":"10.3389\/fimmu.2020.613114","article-title":"Tumor hypoxia regulates immune escape\/invasion:influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies","volume":"11","author":"Abou Khouzam","year":"2021","journal-title":"Front Immunol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/curroncol31010001","article-title":"Overcoming resistance mechanisms to immune checkpoint inhibitors: leveraging the anti-tumor immune response","volume":"31","author":"Coschi","year":"2024","journal-title":"Curr Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/cancers14030539","article-title":"Multifaceted interplay between hormones, growth factors and hypoxia in the tumor microenvironment","volume":"14","author":"Lappano","year":"2022","journal-title":"Cancers"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cells13050413","article-title":"The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC)","volume":"13","author":"Wang","year":"2024","journal-title":"Cells"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"115425","DOI":"10.1016\/j.biopha.2023.115425","article-title":"Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance","volume":"166","author":"Zhao","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.5937\/asn2387555I","article-title":"Association of carcinoma-associated fibroblasts with clinico-pathological parameters of oral squamous cell carcinoma: an immunohistochemical study","volume":"39","author":"Idoska","year":"2023","journal-title":"Acta Stomatol Naissi"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"101717","DOI":"10.1016\/j.tranon.2023.101717","article-title":"Heterogeneity of cancer-associated fibroblasts in head and neck squamous cell carcinoma","volume":"35","author":"Mou","year":"2023","journal-title":"Transl Oncol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/ijms25021300","article-title":"Cancer-associated fibroblast heterogeneity in malignancy with focus on oral squamous cell carcinoma","volume":"25","author":"Arebro","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.3390\/ijms26073234","article-title":"Cancer-associated fibroblasts as the architect of the lung cancer immune microenvironment: multidimensional roles and synergistic regulation with radiotherapy","volume":"26","author":"Shi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10555-024-10186-7","article-title":"Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy","volume":"43","author":"Guo","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","article-title":"Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects","volume":"32","author":"Cao","year":"2025","journal-title":"J Biomed Sci"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/07357907.2023.2237576","article-title":"The impact of cancer-associated fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in bladder cancer: a comparison between recurrent and non-recurrent patient-derived CAFs","volume":"41","author":"Rastegar-Pouyani","year":"2023","journal-title":"Cancer Investig"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3390\/cancers16173047","article-title":"Advancements in TGF-\u03b2 targeting therapies for head and neck squamous cell carcinoma","volume":"16","author":"Britton","year":"2024","journal-title":"Cancers"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"668731","DOI":"10.3389\/fonc.2021.668731","article-title":"Cancer-associated fibroblasts and tumor-associated macrophages in cancer and cancer immunotherapy","volume":"11","author":"Raskov","year":"2021","journal-title":"Front Oncol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.3390\/cancers14163972","article-title":"Recent advances and challenges in cancer immunotherapy","volume":"14","author":"Peterson","year":"2022","journal-title":"Cancers"},{"key":"ref79","first-page":"e68","article-title":"Targets of tumor microenvironment for potential drug development","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"115432","DOI":"10.1016\/j.celrep.2025.115432","article-title":"The tumor microenvironment is an ecosystem sustained by metabolic interactions","volume":"44","author":"Kay","year":"2025","journal-title":"Cell Rep"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","article-title":"Molecular landmarks of tumor hypoxia across cancer types","volume":"51","author":"Bhandari","year":"2019","journal-title":"Nat Genet"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/cells14090673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh","year":"2025","journal-title":"Cells"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s11658-024-00682-7","article-title":"Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3390\/ijms25063313","article-title":"A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update","volume":"25","author":"Magar","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-06-3322","article-title":"Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers","volume":"67","author":"Winter","year":"2007","journal-title":"Cancer Res"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","article-title":"Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer","volume":"14","author":"Liao","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"932055","DOI":"10.3389\/fimmu.2022.932055","article-title":"Lactate from the tumor microenvironment\u2014a key obstacle in NK cell-based immunotherapies","volume":"13","author":"Jedli\u010dka","year":"2022","journal-title":"Front Immunol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.3390\/cancers12113244","article-title":"Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment","volume":"12","author":"P\u00e9rez-Tom\u00e1s","year":"2020","journal-title":"Cancers"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41419-024-06587-9","article-title":"Hypoxia-induced miR-5100 promotes exosome-mediated activation of cancer-associated fibroblasts and metastasis of head and neck squamous cell carcinoma","volume":"15","author":"Duan","year":"2024","journal-title":"Cell Death Dis"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.2147\/IJN.S479533","article-title":"Hypoxia-driven changes in tumor microenvironment: insights into exosome-mediated cell interactions","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomed"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.7150\/thno.62455","article-title":"LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer","volume":"11","author":"Zhu","year":"2021","journal-title":"Theranostics"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-023-02724-y","article-title":"Novel cancer treatment paradigm targeting hypoxia-induced factor inconjunction with current therapies to overcome resistance","volume":"42","author":"Kao","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3390\/ijms25042060","article-title":"Therapeutic targeting of hypoxia-inducible factors in cancer","volume":"25","author":"Musleh Ud Din","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"12990","DOI":"10.3390\/ijms252312990","article-title":"The potential of oncolytic virotherapy in the treatment of head and neck cancer: a comprehensive review","volume":"25","author":"Spirito","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"1533033820980116","DOI":"10.1177\/1533033820980116","article-title":"Tumor vessel normalization: a window to enhancing cancer immunotherapy","volume":"19","author":"Li","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.3390\/cancers13174444","article-title":"Normalizing tumor vasculature to reduce hypoxia, enhance perfusion, and optimize therapy uptake","volume":"13","author":"Matuszewska","year":"2021","journal-title":"Cancers"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"1548588","DOI":"10.3389\/fbioe.2025.1548588","article-title":"Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance","volume":"13","author":"Sabir","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoto.2013.214","volume":"139","author":"Cohen","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1039\/D4MA00122B","article-title":"Hydrogels as local depots for on-demand therapeutic delivery: potential therapeutic approaches for tumor metastasis","volume":"5","author":"Andrgie","year":"2024","journal-title":"Mater Adv"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1080\/10717544.2021.1923863","article-title":"Paclitaxel-loaded polymeric nanoparticles based on \u03b1-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivomurine model","volume":"28","author":"Riestra-Ayora","year":"2021","journal-title":"Drug Deliv"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jconrel.2012.01.045","article-title":"Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth","volume":"159","author":"Rahman","year":"2012","journal-title":"J Control Release"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"293","DOI":"10.31557\/apjcb.2025.10.2.293-299","article-title":"Enhanced anticancer potential of curcumin-loaded liposomal nanoparticles in oral cancer treatment","volume":"10","author":"Moravedeh","year":"2025","journal-title":"Asian Pac J Cancer Biol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12032-025-02746-w","article-title":"The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches","volume":"42","author":"Sheikh","year":"2025","journal-title":"Med Oncol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"101599","DOI":"10.1016\/j.gendis.2025.101599","article-title":"Recent advances in oncolytic virus combined immunotherapy in tumor treatment","volume":"12","author":"Zhou","year":"2025","journal-title":"Genes Dis"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","article-title":"Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery","volume":"24","author":"Sabit","year":"2025","journal-title":"Mol Cancer"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"1522820","DOI":"10.3389\/fimmu.2024.1522820","article-title":"Understanding the tumor microenvironment for personalized immunotherapy in early-onset head and neck squamous cell carcinoma","volume":"15","author":"Shan","year":"2025","journal-title":"Front Immunol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/IJN.S500591","article-title":"Drug delivery system targeting cancer-associated fibroblast for improving immunotherapy","volume":"20","author":"Zhang","year":"2025","journal-title":"Int J Nanomed"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"104380","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"eBioMedicine"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1552337","DOI":"10.3389\/fonc.2025.1552337","article-title":"Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review","volume":"15","author":"Abu Taha","year":"2025","journal-title":"Front Oncol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdy507","article-title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","volume":"30","author":"Oliva","year":"2019","journal-title":"Ann Oncol"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.3390\/cancers15225369","article-title":"A radiomics approach to identify immunologically active tumor in patients with head and neck squamous cell carcinomas","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/pharmaceutics15082166","article-title":"Drug repurposing to circumvent immune checkpoint inhibitor resistance in cancer immunotherapy","volume":"15","author":"To","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.apsb.2021.09.006","article-title":"Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1007\/s10238-023-01051-y","article-title":"Molecular mechanisms of action of metformin: latest advances and therapeutic implications","volume":"23","author":"Zhu","year":"2023","journal-title":"Clin Exp Med"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.3390\/ijms25074083","article-title":"Metformin: a dual-role player in cancer treatment and prevention","volume":"25","author":"Galal","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref133","first-page":"214","article-title":"Prostaglandin E2 inhibits the differentiation of T regulatory cells by Peroxisome Proliferator-Activated Receptor-Gamma during allergic rhinitis","volume":"43","author":"Ju","year":"2025","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cllc.2022.12.013","article-title":"The association of improved overall survival with NSAIDs in non-small cell lung cancer patients receiving immune checkpoint inhibitors","volume":"24","author":"Sebastian","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.3390\/ijms21217958","article-title":"Neurobiology of cancer: the role of \u03b2-adrenergic receptor signaling in various tumor environments","volume":"21","author":"Mravec","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/cancers17081357","article-title":"The impact of beta blockers on survival in cancer patients: a systematic review and meta-analysis","volume":"17","author":"Sharma","year":"2025","journal-title":"Cancers"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BS9.0000000000000117","article-title":"Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis","volume":"4","author":"Nie","year":"2022","journal-title":"Blood Sci"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/CM9.0000000000002909","article-title":"Disulfiram: a novel repurposed drug for cancer therapy","volume":"137","author":"Zeng","year":"2024","journal-title":"Chin Med J"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.3390\/cancers15153948","article-title":"Statins in cancer prevention and therapy","volume":"15","author":"Ricco","year":"2023","journal-title":"Cancers"},{"key":"ref140","first-page":"e2078","article-title":"Statins as anti-tumor agents: a paradigm for repurposed drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-11\/OncolRes-33-11-68395\/OncolRes-33-68395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:23:12Z","timestamp":1763346192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n11\/64078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":140,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.068395","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}